Alzheimer's research tests from Lifescreen:
This article was originally published in Clinica
Executive Summary
Lifescreen (UK) has launched two new products for use in Alzheimer's disease research. The first is an ELISA that can detect as little as 3pg of b-amyloid peptide. The assay comes in a 96-well format and uses a fluorescent substrate to achieve high sensitivity, the company says. The second product is the Synthaloid AD Drug Discovery System for screening products that modify b-amyloid deposition. It uses a b-amyloid polymer matrix to mimic the behaviour of b-amyloid in the brain.